SwissNET - a Registry for Neuroendocrine Tumours in Switzerland

Summary

Gastroentero-pancreatic neuroendocrine tumours (GEP-NETs) are regarded as a fairly rare disease. They are derived from the neuroendocrine system of the gastrointestinal tract and the pancreas and share common clinical features. So far, there is still uncertainty about the cell biology and mechanistic regulation of these tumours. Therefore targeted treatment is limited and management challenging. Treatment options include surgery, medical and ablative therapy, and more recently peptide-receptor radionuclide therapy. In order to better understand the characteristics of GEP-NETs and to evaluate treatment strategies, the SwissNET registry aims at the collection of data from patients presenting with a GEP-NET in Switzerland. Data will be entered prospectively and anonymized in a specifically designed database after the patient has given informed consent. All hospitals and general practitioners are invited to report on patients with a GEP-NET diagnosis and to participate to the registry. Data will be evaluated within regular time frames, focussing on types of GEP-NETs, treatment modalities and patient outcomes (e.g. mortality, hospitalisation rate), thereby contributing to the better understanding of these tumours.

Conditions

• Neuroendocrine Tumors
• Carcinoid Tumor

Sponsors & Collaborators

• Cantonal Hospital of St. Gallen

  collaborator OTHER

• University Hospital, Basel, Switzerland

  collaborator OTHER

• University Hospital, Geneva

  collaborator OTHER

• University of Lausanne Hospitals

  collaborator OTHER

• University Hospital, Zürich

  collaborator OTHER

• Triemlispital Zurich

  collaborator UNKNOWN

• Spitalnetz Bern

  collaborator UNKNOWN

• Ente Ospedaliero Cantonale, Bellinzona

  collaborator OTHER

• Luzerner Kantonsspital

  collaborator OTHER

• Kantonsspital Liestal

  collaborator OTHER

• Kantonsspital Graubuenden

  collaborator OTHER

• Spital Limmattal Schlieren

  collaborator OTHER

• Waid City Hospital, Zurich

  collaborator OTHER

• Spital STS AG

  collaborator INDUSTRY

• Insel Gruppe AG, University Hospital Bern

  lead OTHER

Principal Investigators

• Aurel Perren, MD · Institute of Pathology, University of Bern, Bern

Eligibility

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2008-01-31

Primary Completion

2028-01-31

Completion

2028-01-31

Countries

• Switzerland

Study Locations